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ABSTRACT 32 
Antimicrobial medicated dressings (AMD) are often used to reduce bacterial infection of burns and 33 
other wounds. However, since AMD are medical devices, there is limited literature regarding 34 
comparative efficacies to inform effective clinical decision making. 35 
Objectives 36 
Following on from a previous study where we demonstrated good antibiofilm properties of acetic 37 
acid (AA), we assessed and compared the in vitro anti-biofilm activity of a range of AMDs and non-38 
AMDs to AA. 39 
Methods 40 
Laboratory experiments were used to determinedetermined the ability of a range of eleven 41 
commercial AMD, two nAMD, and AA, to prevent the formation of biofilms of a panel of four isolates 42 
of Pseudomonas aeruginosa and Acinetobacter baumannii. 43 
Results 44 
There is a large variation in ability of different dressings to inhibit biofilm formation, seen both 45 
withbetween dressings that contain the same, and those that contain a variety of other 46 
antimicrobial agents. The best performing AMD were Mepilex® Ag and Acticoat. AA consistently 47 
prevented biofilm formation.  48 
Conclusions 49 
VastLarge variation exists in the ability of AMD to prevent biofilm formation and colonisation of 50 
wounds. A standardised in vitro methodology should be developed for external parties to examine 51 
and compare the efficacies of commercially available AMDs, along with robust clinical randomised 52 
4 
 
controlled trials. This is essential for informed clinical decision-making and optimal patient 53 
management. 54 
Keywords: Antimicrobial, dressings, wounds, burns, biofilms.   55 
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1 INTRODUCTION1 56 
Infection is a significant concern in patients who survive an initial burn insult. This complication of 57 
burn recovery impacts on morbidity, mortality and healthcare costs [1], and in some centres has 58 
been estimated to account for over 75% of the mortality [2].  59 
Burns patients are especially susceptible to infection owing to the injury removing the protective 60 
barrier provided by the skin, combined with general immunosuppression, the presence of 61 
endogenous microflora, prolonged hospital stays, and invasive diagnostic and therapeutic 62 
procedures [3]. Consequently despite careful treatment and infection control practices, burn 63 
wounds are readily colonised with a range of pathogenic micro-organisms, significantly delaying 64 
wound healing, and increasing risks of systemic infection, and graft failure [4].   65 
The most frequently implicated bacteria are Pseudomonas aeruginosa, Acinetobacter baumannii, 66 
Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, and 67 
Enterobacter spp [5, 6]. Of these, P. aeruginosa and A. baumannii are most prevalent [7], with 68 
Lawrence [8] finding P. aeruginosa in one-third of burn wounds, and in 59% of those patients with 69 
extensive burns. Yali et al [9] took clinical samples from burns patients in burn intensive care units 70 
(ICU) and common burn wards and identified the organisms causing infection. 1621 pathogens were 71 
isolated from 2395 clinical samples of the burn ICU, and of these 74.2% were Gram-negative. A. 72 
baumannii was the most prevalent representing 34.4% of all pathogens present in this setting. 73 
Additionally, there is also concern that patients may acquire bacteria with resistance to multiple 74 
systemic antimicrobials, such as the carbapenem resistant Enterobacteriaceae (CRE), for which there 75 
are very limited treatment options.  76 
Colonisation of burn wounds typically occurs as biofilms (communities of bacteria), which are harder 77 
to treat and eradicate owing to reduced rates of metabolism and protection (against antimicrobial 78 
                                                             
1 AMD: antimicrobial dressing; nAMD: non-antimicrobial dressing; AA: acetic acid; ICU: intensive care unit; AM: 
antimicrobial; RCTs: randomised controlled trials; MH: muller-hinton; CV: crystal violet. 
Formatted: Font color: Auto
Formatted: Font color: Auto
6 
 
agents and the immune response) afforded by the polysaccharide matrix [10]. Consequently the 79 
presence of biofilms is associated with persistence of colonisation and increased risk of systemic 80 
infection [1]. Hence, general principles of wound management include appropriate systemic care 81 
(e.g. in terms of pain control, nutrition and control of serum glucose levels in those with diabetes 82 
mellitus), combined with local wound care (especially in terms of preventing colonisation). For burn 83 
wounds, the standard of care worldwide is early excision of necrotic tissues followed by covering the 84 
wound with a medical dressing. Prevention and treatment of bacterial colonisation are key parts of 85 
wound care [11]. 86 
There is a vastlarge array of dressings and a range of factors that govern the choice of dressing that 87 
is most appropriate for wound management (e.g. type of wound, stage of healing process, and 88 
volume of exudate). However, for burns and other wounds where infection is a high risk, 89 
antimicrobial dressings (AMD) may be used. Typically the antimicrobial agent (AM) is contained 90 
within a commercially marketed wound dressing, which can be used both prophylactically (to 91 
prevent colonisation of the wound and subsequent biofilm formation), and in the treatment of 92 
established infection. Systemic administration of antimicrobials is not thought to be necessary nor 93 
useful for the management of local wound infections, since the drugs i) may not penetrate well into 94 
the wounds (due to poor blood flow and the presence of dead tissue) [10], ii) would need to be used 95 
in very high doses (to treat organisms growing in sessile biofilms) [12], and iii) systemic 96 
administration has not been shown to prevent bacterial colonisation [13]. Furthermore, 97 
inappropriate use of systemic antibiotics can be associated with problems of allergy, toxicity and the 98 
development of resistance in non-target organisms.  99 
AMD account for approximately a quarter of all dressings prescribed in primary care in England [14], 100 
and may contain a range of antimicrobial agents (e.g. silver, iodine, honey, and chlorhexidine). The 101 
use of AMD and silver-dressings (which are classed as ‘advanced’ dressings) has risen in recent years, 102 
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with £25 million spent on silver dressings in 2006/7 [10]. Indeed, one in every seven wound dressing 103 
items prescribed by the NHS contain silver as an active agent [10].  104 
Silver (Ag) has been used extensively in burn wound management [15] and is a potent antimicrobial. 105 
Silver-containing dressings vary in their composition and act by a combination of i) absorbing wound 106 
exudates and killing the microorganisms drawn into the dressings, and/or ii) releasing active silver 107 
onto the wound bed. These biologically active ions then bind to negatively charged proteins, RNA, 108 
and DNA and damage bacterial cell walls, inhibit replication and reduce metabolism and growth [16]. 109 
Broad antimicrobial activity has been reported against Gram-positive and Gram-negative organisms 110 
[17], protozoa, viruses [18], and fungi [19].  111 
AMD are marketed as effective against a broad range of bacteria (growing as biofilms) over multiple 112 
days, and are indicated for a variety of serious wounds (e.g. partial thickness burns, ulcers, donor 113 
and graft sites, traumatic, and surgical wounds). Provided that the agent is considered to only 114 
provide an ancillary action on the wound, the majority of dressings (including AMD) are classified as 115 
medical devices [20]. This means there are lesser requirements in terms of robust data from 116 
randomised controlled trials (RCTs) to support safety and efficacy, and literature reviews and 117 
commercial company-led research are often deemed acceptable for licensing. Consequently, there is 118 
little data available in peer-reviewed literature concerning their activity [11]. Unsurprisingly in 119 
clinical practice, opinions on the use of silver dressings are divided, with some clinicians believing 120 
that they have a role to play in preventing infection in burns patients [21, 22, 23], and other experts 121 
not endorsing their use owing to a lack of evidence of effectiveness [10, 24].   122 
Several systematic reviews have been performed looking at use of silver dressings for wound 123 
management with the majority concluding that there is insufficient evidence to recommend using 124 
silver dressings. A systematic review performed by [25] identified 14 RCTs of silver-containing 125 
dressings and topical silver agents (used with dressings) for burn wounds, and despite significantly 126 
better healing with silver compared to the control in one small trial, they concluded that silver-127 
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containing dressings were either no better, or were worse than control dressings in preventing 128 
wound infection. Indeed, a Cochrane Review from 2010 looking at topical silver products (dressings 129 
and creams) identified 26 RCTs (20 of which were on burns), and concluded that there was 130 
‘insufficient evidence to support the use of silver containing dressings or creams, as generally they 131 
did not promote wound healing or prevent wound infections’ [26]. However, despite these findings, 132 
clinicians are still using silver dressings perhaps owing to the extensive marketing and promotion of 133 
these commercial dressings [27], and the absence of any alternatives.  134 
In addition to silver, AMD may contain iodine/povidone-iodine (which rapidly penetrates 135 
microorganisms, damaging proteins, nucleotides and fatty acids, leading to rapid cell death) [28], 136 
honey (which is antimicrobial due to osmotic effect, a low pH and the production of hydrogen 137 
peroxide [29]), or chlorhexidine; which binds to and disrupts the negatively charged bacterial cell 138 
wall and affects the osmotic equilibrium of the cell [30].  Furthermore, in addition to commercial 139 
AMD, biocidesother biocide-impregnated dressings may have a role to play in preventing wound 140 
infection.  A range of biocides have been investigated in this regard (e.g. silver nitrate, mafenide 141 
acetate, povidine iodine, silver sulfadiazine and chlorhexidine), including acetic acid (CH3COOH).  142 
Acetic acid (AA), or vinegar, has been used sporadically in medicine for the past 6000 years [4], being 143 
successfully implemented to treat plague, ear, chest, and urinary tract infections [31, 32, 33],  and in 144 
the elimination of Bacillus pyocyaneus (now Pseudomonas aeruginosa) from war wounds [7].  We 145 
have used AA for a decade in our burns centre at a concentration of 2.5% to treat patients with burn 146 
wounds infected or heavily colonised with P. aeruginosa. Here it is applied topically within dressings, 147 
is well-tolerated by patients, and is observed to have good clinical outcomes. Additionally, AA is 148 
currently used in a number of lesser economically developed countries (LEDCs) and other resource-149 
limited settings for burn wound management.  150 
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 Following a recent study on the anti-biofilm properties of AA as a topical AM agent, we sought to 151 
assess and compare the anti-biofilm properties of AA versus the AMDs currently used in our Burns 152 
Centre at the Queen Elizabeth Hospital, Birmingham.  153 
We aimed to compare efficacy to help guide clinical practice at our centre and others.  154 
 155 
2 METHODS 156 
A series of in vitro experiments were conducted to determine the efficacy of the AMD in terms of 157 
their ability to prevent biofilm formation. AA (in a range of concentrations from 5% down to 0.02%) 158 
was included as a comparator following on from previous research [Halstead et al, unpublished] 159 
which demonstrated AA to be effective at preventing biofilm formation when used from 5% down to 160 
concentrations as low as 0.31% (w/v).  Plain dressings that contained no antimicrobial agent (herein 161 
referred to as nAMD) were also included as comparators. 162 
Four organisms were tested (two Pseudomonas aeruginosa and two Acinetobacter baumannii) 163 
(Table I), and comprised well-characterised control strains (PS_PA01, ACI_AYE) and clinical isolates 164 
from burns patients (ACI_721, PS_1586). All AM products (Table II) were freshly opened and were 165 
within date when used. Experiments were performed using at least two biological replicates, and at 166 
least four technical replicates of each isolate.   167 
 168 
2.1    Processing of the AMDs 169 
The following AMD were prepared for testing: Mepilex® Ag (Mölnlycke Healthcare), Aquacel® Ag, 170 
Aquacel® Ag Foam, Aquacel® Ag Burn (all Convatec), UrgoTul® Silver (Urgo Medical), Acticoat (Smith & 171 
Nephew), PolyMem Silver® (Ferris MFG. Corp.), Inadine® (Systagenix), L-Mesitran® Net, L-Mesitran® 172 
Hydro (both from L-Mesitran Wound Care), and Bactigras (Smith & Nephew). This involved carefully 173 
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cutting the sterile dressing into a number of 1cm2 pieces (so that there was sufficient for 1 piece per 174 
test well) using a sterile scalpel or a pair of flame sterilised scissors. The nAMD; UrgoTul® (Urgo 175 
Medical), and PolyMem® (Ferris MFG. Corp.), were prepared in the same way.  176 
Details of these dressings (and references to published work) are in Table II.  177 
 178 
2.2    Impact of the AMD and AA on biofilm formation  179 
The ability of the range of AMD and AA to prevent biofilm formation was assessed using a crystal 180 
violet biofilm formation assay as described by Baugh et al [34].  181 
Overnight cultures of the test strains (grown in 5ml of Lysogeny (LB) broth [Oxoid]) were diluted in 182 
fresh antibiotic-free Muller-Hinton (MH) broth [Oxoid] to an optical density at 600nm (OD600) of 0.1, 183 
and then 1ml was seeded into wells of a 24-well MTT [Corning, New York], alongside 1ml of either 184 
diluted AA (water as diluent) or sterile water. AA was tested at the following dilutions: 5%, 2.5%, 185 
1.25%, 0.63%, 0.31%, 0.16%, 0.08%, 0.04%, 0.02% and 0.01%. For the AMD test wells, one piece of 186 
dressing was placed into the well containing the organism suspension and water to provide a total 187 
volume of 2mls plus dressing.  188 
Suitable controls were included in each assay, comprising 1ml overnight bacterial culture with 1ml 189 
water (for the positive control), or 2mls MH broth with no bacteria (for the negative control).  190 
Plates were sealed and statically incubated at (33°C); the temperature of the surface of a wound 191 
[35]. After 72 hours, the liquid and AMD pieces were removed from the wells and the plates rinsed 192 
in tap water to remove any unbound cells. Any existing biofilms were then visualised through 193 
staining with 2mls of 1% crystal violet (CV) [Sigma Aldrich, Poole, UK], further rinsed (as above) to 194 
remove unbound CV, and dye solubilised by the addition of 2mls of 70% ethanol.  200ul from each 195 
well was then transferred into wells of a 96-well microtitre tray, and the OD600 of the solubilised CV 196 
11 
 
solution was then measured using a FLUOstar Optima [BMG Labtech] to assess the biomass of the 197 
biofilms.  198 
The positive and negative controls for each test plate were examined and if within a normal range 199 
the rest of the data was analysed for percentage change in biofilm biomass, and for statistical 200 
significance, by comparing values for each AMD, and at each concentration of AA to untreated 201 
(positive) controls using the students’ ‘t’ test.Students’ ‘t’ test. Adjustments for multiple 202 
comparisons were made to control the family-wise error rate for each of the four groups of tests 203 
using Holm’s method [36]. 204 
 205 
3    RESULTS 206 
All four of the bacterial isolates (PS_PA01, PS_1586, ACI_AYE and ACI_721) were tested against all 207 
the AMD, nAMD and AA achieving at least four, but up to ten technical replicates. The 208 
numbernumbers of replicates can be seen in parenthesis in tableare shown on tables III. and IV for P. 209 
aeruginosa, and A. baumannii, respectively.  210 
The mean average optical densities of the solubilised CV were plotted per species for A. baumanniii, 211 
and P. aeruginosa, and are shown in figures 1 and 2, respectively for the dressings, and figures 3 and 212 
4 for the AA and best/worst performing dressings against each species, respectively. The standard 213 
error bars (denoting variation in the number of technical replicates) are also plotted and all data has 214 
been normalised by subtraction of the negative (broth only) control.  215 
The graphs demonstrate that there is a large variation in the test agents (AMD, nAMD and AA) in 216 
terms of reducing biofilm formation (e.g. from an increase of 33% with L-Mesitran® Net to a decrease 217 
of 100% with Acticoat and Mepilex® Ag for ACI_721). This is seen both withbetween different 218 
dressings that contain the same active agent (e.g silver) (e.g. from an increase of 43% with PolyMem 219 
Silver® to a decrease of 100% with Acticoat and Mepilex® Ag for PS_PA01) and between those that 220 
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contain a variety of otherdifferent AM agents. This data is also shown in table III which provides 221 
percentage differences in biofilm biomass, and statistical significance (p≤0.05) when the difference 222 
in biofilm biomass for each dressing/agent was compared to the positive control. The p-values in 223 
tables III and IV are adjusted for multiple comparisons to control the error rate. 224 
Generally all AMD showed similar activity against both representatives of each species. 225 
3.1 Performance of the silver-containing AMD 226 
Seven silver-containing AMDs were tested and the majority showed some effectiveness at reducing 227 
biofilm formation (tabletables III & IV, figures 1 & 2). For both species and all four isolates, Mepilex® 228 
Ag (Mölnlycke Healthcare), and Acticoat (Smith & Nephew) were highly effective, leading to 90-229 
100% reduction of biofilm formation compared to the positive control. These results were highly 230 
consistent across all replicates as shown by the small error bars, and were also statistically significant 231 
in the t-tests with all p-values ≤0.05.  232 
For the Aquacel® dressings (Ag, Ag foam and Ag burn), the reductions were generally modest, 233 
averaging 44% for PS_PA01 and 34% for PS_1586. The A. baumannii isolates appear to be more 234 
susceptible to these dressings with average reductions of 77% for ACI_721, and 65% for ACI_AYE. 235 
The results for Aquacel® Ag burn against biofilms of ACI_AYE show reductions of 94% (statistically 236 
significant with adjusted p-values <0.05), and small standard error across all six replicates.  237 
In general UrgoTul® Silver (a thin mesh-like AMD) was able to reduce biofilm formation for the 238 
majority of the isolates and replicates. However, for PS_1586, for four of the eight replicates, there 239 
was an increase in biofilm biomass in wells containing the dressings. This ranged from 13-80% (data 240 
not shown). PolyMem Silver® also gave varied results, with reductions in biomass of biofilms 241 
apparent with the A. baumannii isolates (61% reduction for ACI_AYE and 75% for ACI_721), but 242 
increases noted with both the P. aeruginosa isolates (43% increase in biofilm biomass for PS_PA01, 243 
and 11% increase for PS_1586).  244 
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 245 
3.2 Performance of the non-silver containing AMD 246 
The four non-silver containing AMD gave varied results. Inadine® (Systagenix), which contains 247 
povidone-iodine as the active agent, slightly reduced biofilm formation for the two clinical isolates 248 
(ACI_721 and PS_1586 and ACI_721) by 6 and 10% respectively, but this was not statistically 249 
significant, and the dressing was ineffective against the control strains.  250 
The honey-containing dressings of L-Mesitran® Net and L-Mesitran® Hydro (both from L-Mesitran 251 
Wound Care) were generally ineffective at preventing biofilm formation. Although reduced biofilm 252 
formation occurred with A. baumannii ACI_AYE for both dressings with a maximum reduction of 253 
10.4% (not statistically significant, p values >0.05), and ACI_721 (where there was a statistically 254 
significant reduction (adjusted p = 0.004038) of 62% in biofilm biomass with L-Mesitran® Hydro 255 
compared to the positive control), both dressings were ineffective at preventing biofilm formation of 256 
P. aeruginosa. For both isolates increased biofilm formation occurred, ranging from 20% with L-257 
Mesitran® Net and PA_1586 to 200% with L-Mesitran® Hydro and this same isolate. L-Mesitran® 258 
Hydro was the worst performer, with an average 115% increase in biofilm biomass for PS_PA01, and 259 
average 200% increase for PS_1586 (Table III).   260 
Bactigras (the only chlorhexidine-containing dressing) generally reduced biofilm formation, with 261 
statistically significant reductions of 39, 59 and 68% for PS_PA01, ACI_AYE and ACI_721, 262 
respectively. (with this latter reduction statistically significant with an adjusted p-value of 0.038). It 263 
was however ineffective for PS_1586, where there was an average 200% increase in biofilm biomass.  264 
 265 
3.3 Performance of the AMD vs the nAMD 266 
Despite not containing an AM agent, both of the nAMD reduced biofilm formation in this experiment 267 
for the P. aeruginosa (PS_1586), and A. baumannii (ACI_AYE and ACI_721) isolates. Reductions 268 
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ranged from 7% to 74%, but were generallyonly statistically significant for ACI_721, where the 74% 269 
reduction is associated with an adjusted p-value of 0.003 (table III) andIV).  Some of the reductions 270 
were higher than those seen with some of the marketed AMDs. For example for ACI_AYE721, 271 
Inadine®, L-Mesitran® Net and L-Mesitran® Hydro resulted in differences of +3, -10.4-6, +33, and -272 
162%, compared to the nAMD (PolyMem® plain) where there was a 6674% reduction in biofilm 273 
biomass (statistically significant, p=0.003).  274 
For PS_PA01, there was no reduction in biofilm biomass with the nAMD (table III). 275 
 276 
3.4 Performance of the AMD compared to AA 277 
The shaded cells in tabletables III and IV highlight the data where there was reduction in biofilm 278 
formation by at least 90%. Acetic acid performs well as an anti-biofilming agent, with reductions of 279 
≥90% seen for concentrations of AA from 5% down to 0.16% (0.08% for ACI_721). This result was 280 
consistent across all replicates. 281 
Graphs 3 and 4 show the optical density of the biofilm biomass produced following incubation of the 282 
cultures with the various concentrations of AA alongside the most and least effective of the AMDs 283 
(Acticoat and L-Mesitran® Net for A. baumannii, and Mepilex® Ag and L-Mesitran® Hydro for P. 284 
aeruginosa).  285 
The data demonstrate that AA out performs the L-Mesitran® dressings in terms of reducing biofilm 286 
formation, and compares favourably to the best-performing AMD (Acticoat and Mepilex® Ag).  287 
4    DISCUSSION 288 
Medicated AMDs have the potential to significantly reduce bacterial contamination of burns and 289 
wounds; a post-insult complication that may delay wound healing, and lead to widespread systemic 290 
infection [3637]. Despite being a small study, this work has demonstrated that in the in vitro setting 291 
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there is a large variation in the ability of commercial AMD to prevent biofilm formation of two key 292 
burn wound pathogens. Biofilm formation is a key contributor to wound colonisation and 293 
subsequent infection. 294 
Although not concerning biofilms, Cavanagh et al [11] found similar results when they tested the 295 
antimicrobial efficacy of a range of silver dressings (Mepilex® Ag, Algicell™ Ag, PolyMem Silver®, 296 
Biostep™ Ag, and Acticoat) against planktonic forms of growth.  In a log-reduction assay (from 297 
Gallant-Behm et al [3738]), they determined the ability of commercial silver AMD to kill 298 
Staphylococcus aureus in 30 minutes. They noted a large variation in average log reduction between 299 
the silver dressings and concluded that Acticoat was the only bactericidal dressing.  300 
Here we show that the silver dressings were the most effective at preventing biofilm formation, with 301 
Mepilex® Ag and Acticoat consistently outperforming the other AMD and reducing biofilm formation 302 
by at least 90%. A review of the literature shows that many comparisons of silver dressings have 303 
drawn similar conclusions regarding efficacy of Acticoat. For example Gallant-Behm et al [3738] 304 
found that Acticoat was the only bactericidal dressing of eight that were tested.  305 
 Lesser reductions in biofilm formation were seen with the other silver-containing AMD, although 306 
the results were still mostly statistically significant when compared to the positive control. The worst 307 
performing AMDs were the honey-containing dressings, where there was little, if any, observable 308 
benefit over the two nAMD. Additionally, the study has provided further evidence that AA can 309 
prevent the formation of biofilms by key burn wound pathogens, and has indicated that this activity 310 
compares favourably to the best performing AMDs. The antimicrobial effect of AA against planktonic 311 
and biofilm growth modes of bacteria has been reported previously [38, 39, 40], but comparison to 312 
AMD is a new finding.  313 
To further build up this evidence baseIn future, it would be useful to perform a number of  well 314 
controlled studies that take into consideration the exact dressing volume and quantities of AM agent 315 
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that are released. In this study dressings were measured using a ruler and cut to 1cm2, but their 316 
volumes were not considered. A number of the dressings are thick foam (Mepilex® Ag, Aquacel® Ag 317 
Foam, PolyMem Silver® and PolyMem®), and hence the tested volume of these dressings would have 318 
been considerably more than that of the thinner dressings (the remainder of the panel). Additionally 319 
the dressings were used in the experiment as they would have been in the clinical setting and 320 
therefore, no allowance was made for the quantity of the AM agent released from the dressings, nor 321 
the site or mode of release. Cavanagh et al [11] performed a silver-dissolution assay and report the 322 
24-hour silver release for Mepilex® Ag and Acticoat as 0.698 and 0.144 mg/cm2, respectively, 323 
compared to 0.00014 mg/cm2 for PolyMem Silver®.  Our findings suggest that the amount of 324 
released silver could be an important determinant of anti-biofilming activity and therefore future 325 
studies should be done to measure the silver release from the dressings throughout the course of 326 
the 72 hour experiment.  327 
 328 
Although an in vitro experiment is unlikely to mimic biofilm formation in the in vivo setting, the 329 
experimental model used was most appropriate for testing the dressings based on the release of the 330 
active antimicrobial agent into ‘exudate’. Additional experiments should be performed to assess 331 
antibiofilm properties of dressings that rely on contact with a solid surface for release of the 332 
antimicrobial agent, and should also test a larger panel of Gram-negative organisms as well as some 333 
Gram-positives organisms such as S. aureus and Enterococcus spp. Furthermore, experiments should 334 
also be conducted on pre-formed biofilms to test efficacy of the AMD and AA against established 335 
bacterial colonisation of burn wounds.  336 
 337 
It should be remembered that there are many factors that govern the choice of dressing, and indeed 338 
the choice of AMD. Although important, bacterial load reductions are only one aspect of wound 339 
healing, and therefore despite showing that certain dressings are better than others for bacterial 340 
reduction, this is only one consideration for a clinician choosing a dressing.  341 
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 342 
5 CONCLUSIONS 343 
The NHS spends a large amount of an ever-pressured budget on commercial AMD, and especially 344 
those that contain silver. This is despite a range of publications and systematic reviews concluding 345 
that there is no robust evidence that dressings containing AM agents (silver, iodine or honey) are 346 
more effective than unmedicated dressings for the prevention or treatment of wound infection [10].  347 
This work has shown that there is a vastlarge variation in the ability of commercial AMD to prevent 348 
biofilm formation and therefore colonisation of wounds, and that a number of the AMD are not able 349 
to prevent biofilm formation and are no better than the nAMD. We have also shown that AA 350 
consistently prevents biofilm formation for all isolates with low error bars and lower cost than the 351 
AMD (data not included).  352 
Given their classification as medical devices, and the subsequent paucity of reliable and unbiased 353 
data on their effectiveness, a standardised in vitro methodology should be developed in order for 354 
external parties to examine and compare the efficacies of the commercial AMDs, along with robust 355 
clinical randomised controlled trials. These are essential for informed clinical decision-making and 356 
optimal patient management.  357 
 358 
Clinicians should be wary of the use of AMDs (if intended to prevent or treat infections) in the 359 
absence of data showing anti-biofilm efficacy, since the longer a biofilm is present, the greater 360 
potential there is for systemic infection to occur.  361 
 362 
 363 
 364 
 365 
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Table I: List of the control and clinical isolates used in this study 490 
 491 
  492 
Study Identifier Organism Description 
PS_PA01 Pseudomonas aeruginosa Control strain [ATCC_15692]. 
Originally isolated from an infected 
wound.  
 
PS_1586 Pseudomonas aeruginosa QEHB Clinical burn wound isolate.  
 
 
ACI_AYE Acinetobacter baumannii 
 
Control strain [ATCC® BAA-1710].  
Originally isolated from human blood.  
 
ACI_721 Acinetobacter baumannii QEHB Clinical burn wound isolate.  
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Dressing [Agent] Supplier Antimicrobial agent and formulation Reports/References  
Mepilex® Ag  
[Silver] 
Mölnlycke 
Healthcare 
Silver sulphate (Ag2SO4) dressing. Thick, soft 
silicone foam dressing  
Dressing inactivates a wide range of bacteria within 30 
minutes, provides a rapid and sustained silver release, can be 
worn for  7 days and does not stain [4041] 
 
Aquacel® Ag  
[Silver] 
Convatec Ionic silver impregnated hydrofibre pad composed 
of sodium carboxymethylcellulose and 1.2% ionic 
silver  
AQUACEL® Ag Foam dressings contain ionic silver to kill a wide 
variety of micro-organisms, (including certain tested antibiotic-
resistant bacteria) within 30 minutes, and provide sustained 
bacterial killing for up to seven days. [41 [42] 
 
Aquacel® Ag Foam 
[Silver] 
Convatec As above As above 
Aquacel® Ag Burn  
[Silver] 
Convatec As above  As above  
 UrgoTul® Silver 
[Silver] 
Urgo Medical Hydrocolloid dressing consisting of a polyester 
web, impregnated with carboxylmethyl cellulose, 
Vaseline and silver.  
 
Many reports [See JWC educational supplement]. An example 
is 102 patients with critically colonised venous leg ulcers who 
were treated with Urgotul Silver versus plain Urgotul. After 8 
weeks, there was a significantly greater reduction in wound 
size in the Urgotul Silver group (p=0.002) as well as fewer 
clinical signs of critical colonisation (p<0.001).  
 
Acticoat  
[Silver] 
Smith & 
Nephew 
Nanocrystalline silver impregnated pad consisting 
of three layers 
Dressing kills bacteria in vitro in 30 minutes, acts as an 
antibacterial barrier for up to 3 days, provides sustained silver 
release, and is effective against over 150 microorganisms 
(Gram-positive, Gram-negative, yeasts and molds) [4243].   
PolyMem Silver®  
[Silver] 
Ferris MFG. 
Corp. 
Polyurethane membrane matrix containing F68 
surfactant, glycerol, a starch copolymer and silver. 
 
Inadine® 
[Iodine] 
Systagenix Low adherent knitted viscose fabric impregnated 
with a polyethylene glycol (PEG) base containing 
10% povidone iodine (combination of 
polyvinylpyrrolidone and elemental iodine). 
 
 
Broad spectrum of activity against Gram-positive and Gram-
negative bacteria, anaerobes, yeast, fungi and spores [4344].  
 
Table II: List of the dressings/agents used in this study alongside their supplier, antimicrobial agent and formulation, and reports/references on their activity 
27 
 
 493 
 494 
 495 
 496 
Dressing [Agent] Supplier Antimicrobial agent and formulation Reports/References  
L-Mesitran® Net  
[Honey] 
L-Mesitran 
Wound Care 
Non-adherent open polyester mesh coated with a 
thin layer of L-Mesitran® Hydro gel.  
 
L-Mesitran is a broad-spectrumantimicrobialspectrum 
antimicrobial, effective against most bacteria including MRSA 
and VRE [4445] 
L-Mesitran® Hydro 
[Honey] 
L-Mesitran 
Wound Care 
Hydrogel sheet (1mm thick) attached to a semi 
polyurethane membrane by a thin fibrous bonding 
layer. The hydrogel contains 30% of medical grade 
honey.  
As above 
Bactigras 
[Chlorhexidine] 
 
Smith & 
Nephew 
Chlorhexidine Acetate BP 0.5% in white soft 
paraffin BP. 
Bacteriostatic and bactericidal. Chlorhexidine acetate has been 
shown to be active, in vitro, against a wide range of Gram-
positive and Gram-negative bacteria at concentrations of 10-50 
µg/ml. These include: Streptococcus pyogenes, Enterococcus 
faecalis, Corynebacterium diphtheriae, Strep. pneumoniae, S. 
aureus, Proteus vulgaris,  E. coli, and  P. aeruginosa [4546] 
UrgoTul® plain 
[No AM agent] 
 
Urgo Medical n/a n/a 
PolyMem®  plain 
[No AM agent] 
 
Ferris MFG. 
Corp. 
n/a n/a 
Acetic acid 
 (5% stock) 
 
Tayside 
Pharmaceuticals 
Acetic acid ( CH3COOH) Bactericidal and active against biofilms when used at low 
concentration for a range of important burn wound pathogens 
[38, 39, 40].  
Formatted: Font: Italic
Formatted: Font: Italic
28 
 
  497 
29 
 
Dressing/agent P. aeruginosa PA01  P. aeruginosa PA_1586 
Dressing/agent Percentage 
change in 
biofilm 
biomass∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
 P. aeruginosa A. baumannii 
 PA01 PA_1586 AYE ACI_721 Mepilex
® Ag  
 
-100 
(8)* 
8 <0.00
1 
0.001 Yes  -99.9 
(6)* 
-95.9 (8)* -100 
(6)* 
<0.00
1 
0.001 Yes 
Aquacel® Ag  
 
-49 
(8)* 
8 0.001 0.012 Yes  -35 (6) -39 (8) -74
(6)* 
0.131 1.000 - 
Aquacel® Ag 
Foam 
 
-21 
(8)* 
8 0.064 0.635 -  -36 (6)* -66 (8)* -74 
(6)* 
0.005 0.078 - 
Aquacel® Ag 
Burn  
 
-63 
(6)* 
6 0.020 0.219 -  -31 (4) -94 (6)* -82 
(4)* 
0.601 1.000 - 
 UrgoTul® 
Silver 
 
-47 
(10)* 
10 0.002 0.029 Yes  +16 (8) -20 (10) -4 (8)  0.457 1.000 - 
Acticoat  
 
-100 
(8)* 
8 <0.00
1 
0.001 Yes  -94 (6)* -96 (8)* -100 
(6)* 
<0.00
1 
0.005 Yes 
PolyMem 
Silver®  
 
+43 (8) 8 0.432 1.000 -  +11 (6) -61 (8)* -75 
(6)* 
0.521 1.000 - 
Inadine® 
 
+3 (8) 8 0.488 1.000 -  -10 (6) +3 (8) -6 (6) 0.609 1.000 - 
L-Mesitran® 
Net  
 
+38 (6) 6 0.808 1.000 -  +20 (4) -10.4 
(6) 
+33 
(4)0.5
50 
1.000 - 
L-Mesitran® 
Hydro 
 
+115 
(8) 
8 0.148 1.000 -  +200 (6) 6 0.316 -1 
(8).00
0 
-62 (6)* 
 
Bactigras 
 
-39 
(8)* 
8 0.005 0.070 -  +200 (6) -59 
(8)*6 
-68 
(6)* 
0.292 
1.000 - 
UrgoTul® 
plain 
 
+56 (4) 4 0.139 1.000 -  -17 (4)* -7 (6) -27 (4) 
 
0.051 0.660 - 
PolyMem®  +39 (6) 6 0.665 1.000 -  -27 (4)* -66 (6)* -74 0.055 0.660 - 
Table III: Table showing the percentage (%) change in biofilm biomass for each of the isolates when 
coincubated with each of the AMD, nAMD or AA for 72 hours, when compared to an untreated, positive 
control.  
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 498 
 499 
 500 
  501 
plain 
 
(4)* 
Acetic acid 5%Table legend:  ∆ where – refers to reduction in biofilm biomass, and + to increase in 
biofilm biomass   ^ original p-values from the Student’s T-test, * p-values adjusted for multiple 
comparisons using Holm’s method, • column shows  dressings with an adjusted p-value<0.05 
-86 (8)* -88 (8)* -92 (10)* -90 (8)* 
 
Acetic acid 2.5% -90 (8)* -91 (8)* -93 (10)* -92 (8)* 
 
Acetic acid 1.25% -94 (8)* -90 (8)* -93 (10)* -93 (8)* 
 
Acetic acid 0.63% -94 (8)* -94 (8)* -93 (10)* -96 (8)* 
 
Acetic acid 0.31% -95 (8)* -97 (8)* -93 (10)* -96 (8)* 
 
Acetic acid 0.16% -96 (8)* -86 (8)* -90 (10)* -94 (8)* 
 
Acetic acid 0.08% 
 
-64 (8)*  -23 (8)* -28 (10) -95 (8)* 
Acetic acid 0.04% 
 
+35 (8) +5 (8) +10 (10) +5 (8) 
Acetic acid 0.02% 
 
+42 (8) -7 (8) +6 (10) +13 (8) 
Acetic acid 0.01% 
 
+67 (6) +11 (4) -30 (4) +7 (4) 
Table III: Table showing the percentage (%) change in biofilm biomass for each of the Pseudom           
nAMD or AA for 72 hours, when compared to an untreated, positive control.  
Table III footnote: + and – refer to increases and decreases in biomass, respectively, with the  
of replicates shown in parenthesis. Asterisks (*) denote statistically significant changes in bio  
(when compared to the positive control , and shaded cells represent reductions of 85% or gre    Formatted: Left, Position: Horizontal:
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  505 
Dressing/agent 
P. aeruginosa PA01  P. aeruginosa PA_1586 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Acetic acid 5% 
 
-86 8 <0.001 0.003 Yes -88 8 <0.001 <0.001 Yes 
Acetic acid 2.5% 
 
-90 8 <0.001 0.002 Yes -91 8 <0.001 <0.001 Yes 
Acetic acid 1.25% 
 
-94 8 <0.001 0.002 Yes -90 8 <0.001 <0.001 Yes 
Acetic acid 0.63% 
 
-94 8 <0.001 0.001 Yes -94 8 <0.001 <0.001 Yes 
Acetic acid 0.31% 
 
-95 8 <0.001 0.001 Yes -97 8 <0.001 <0.001 Yes 
Acetic acid 0.16% 
 
-96 8 <0.001 0.001 Yes -86 8 0.001 0.011 Yes 
Acetic acid 0.08% 
 
-64 8 0.006 0.074 - -23 8 0.035 0.491 - 
Acetic acid 0.04% 
 
+35 8 0.783 1.000 - +5 8 0.653 1.000 - 
Acetic acid 0.02% 
 
+42 8 0.673 1.000 - -7 8 0.298 1.000 - 
Acetic acid 0.01% 
 
+67 6 0.103 0.928 - +11 4 0.589 1.000 - 
32 
 
Dressing/agent 
A. baumannii AYE  A. baumannii ACI_721 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Mepilex® Ag 
 
-95.9 8 <0.001 0.001 Yes -100 6 <0.001 <0.001 Yes 
Aquacel® Ag 
 
-39 8 0.150 1.000 - -74 6 <0.001 0.006 Yes 
Aquacel® Ag Foam 
 
-66 8 0.027 0.295 - -74 6 0.001 0.010 Yes 
Aquacel® Ag Burn 
 
-94 6 0.002 0.031 Yes -82 4 0.003 0.032 Yes 
UrgoTul® Silver 
 
-20 10 0.721 1.000 - -4 8 0.970 1.000 - 
Acticoat 
 
-96 8 <0.001 0.002 Yes -100 6 <0.001 <0.001 Yes 
PolyMem Silver® 
 
-61 8 0.007 0.090 - -75 6 <0.001 0.001 Yes 
Inadine® 
 
+3 8 0.880 1.000 - -6 6 0.820 1.000 - 
L-Mesitran® Net 
 
-10.4 6 0.469 1.000 - +33 4 0.055 0.385 - 
L-Mesitran® Hydro 
 
-1 8 0.926 1.000 - -62 
 
6 0.004 0.038 Yes 
Bactigras 
 
-59 8 0.012 0.148 - -68 
 
6 0.004 0.038 Yes 
UrgoTul® plain 
 
-7 6 0.471 1.000 - -27 
 
4 0.068 0.405 - 
PolyMem®  plain 
 
-66 6 0.004 0.054 - -74 4 <0.001 0.003 Yes 
Table legend:  ∆ where – refers to reduction in biofilm biomass, and + to increase in biofilm biomass   ^ original p-values from the Student’s T-test, * p-values adjusted 
for multiple comparisons using Holm’s method, • column shows  dressings with an adjusted p-value<0.05 
Table IV: Table showing the percentage (%) change in biofilm biomass for each of the Acinetobacter baumannii isolates when coincubated with each of the AMD, 
nAMD or AA for 72 hours, when compared to an untreated, positive control.  
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 507 
 508 
 509 
Dressing/agent 
A. baumannii AYE  A. baumannii ACI_721 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Percentage 
change∆ 
 
Number of 
replicates 
T-test 
p-value^ 
Adjusted 
p-value* 
Adjusted 
significance• 
Acetic acid 5% 
 
-92 10 <0.001 <0.001 Yes -90 
 
8 <0.001 <0.001 Yes 
Acetic acid 2.5% 
 
-93 10 <0.001 0.001 Yes -92 
 
8 <0.001 <0.001 Yes 
Acetic acid 1.25% 
 
-93 10 <0.001 <0.001 Yes -93 
 
8 <0.001 <0.001 Yes 
Acetic acid 0.63% 
 
-93 10 <0.001 <0.001 Yes -96 
 
8 <0.001 <0.001 Yes 
Acetic acid 0.31% 
 
-93 10 <0.001 <0.001 Yes -96 8 <0.001 <0.001 Yes 
Acetic acid 0.16% 
 
-90 10 <0.001 0.001 Yes -94 
 
8 <0.001 <0.001 Yes 
Acetic acid 0.08% 
 
-28 10 0.273 1.000 - -95 8 <0.001 <0.001 Yes 
Acetic acid 0.04% 
 
+10 10 0.260 1.000 - +5 8 0.404 1.000 - 
Acetic acid 0.02% 
 
+6 10 0.220 1.000 - +13 8 0.157 0.787 - 
Acetic acid 0.01% 
 
-30 4 0.838 1.000 - +7 4 0.541 1.000 - 
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Figure legends  510 
Figure 1: Graph showing the mean average biomass of the biofilms produced by the A. baumannii 511 
isolates as measured through the crystal violet assay   512 
Optical density on the y axis refers to the average biofilm biomass for the A. baumannii isolates 513 
when tested with the range of agents shown on the x axis. All the data has been normalised by 514 
subtraction of the negative control and error bars (showing the standard error) have been provided. 515 
Test agents have been grouped according to the active antimicrobial agent present.  516 
 517 
Figure 2: Graph showing the mean average biomass of the biofilms produced by the P. aeruginosa 518 
isolates as measured through the crystal violet assay   519 
Optical density on the y axis refers to the average biofilm biomass for the P. aeruginosa isolates 520 
when tested with the range of agents shown on the x axis. All the data has been normalised by 521 
subtraction of the negative control and error bars (showing the standard error) have been provided. 522 
Test agents have been grouped according to the active antimicrobial agent present.  523 
 524 
Figure 3: Graph showing the mean average biomass of the biofilms produced by the A. baumannii 525 
isolates as measured through the crystal violet assay   526 
Optical density on the y axis refers to the average biofilm biomass for the A. baumannii isolates 527 
when tested with the AA and the best/worst performing dressings shown on the x axis. All the data 528 
has been normalised by subtraction of the negative control and error bars have been provided.  529 
 530 
 531 
 532 
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Figure 4: Graph showing the mean average biomass of the biofilms produced by the P. aeruginosa 533 
isolates as measured through the crystal violet assay   534 
Optical density on the y axis refers to the average biofilm biomass for the P. aeruginosa isolates 535 
when tested with the AA and the best/worst performing dressings shown on the x axis. All the data 536 
has been normalised by subtraction of the negative control and error bars have been provided.  537 
 538 
